Amyris (NASDAQ:AMRS)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a note issued to investors on Thursday, January 18th. They currently have a $15.00 price target on the biotechnology company’s stock. HC Wainwright’s price target would suggest a potential upside of 195.86% from the company’s previous close.
A number of other research firms have also commented on AMRS. Cowen reiterated a “hold” rating and set a $4.00 price objective on shares of Amyris in a research note on Wednesday, November 29th. ValuEngine lowered shares of Amyris from a “sell” rating to a “strong sell” rating in a research note on Friday, December 1st. Finally, Zacks Investment Research upgraded shares of Amyris from a “hold” rating to a “buy” rating and set a $3.75 price objective on the stock in a research note on Wednesday, October 4th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and two have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $7.69.
Amyris (NASDAQ AMRS) opened at $5.07 on Thursday. Amyris has a 12 month low of $1.86 and a 12 month high of $10.70. The company has a current ratio of 0.92, a quick ratio of 0.82 and a debt-to-equity ratio of -0.78. The company has a market cap of $218.18, a P/E ratio of -0.82 and a beta of 0.49.
In other Amyris news, insider John Melo sold 10,776 shares of Amyris stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $4.68, for a total value of $50,431.68. Following the transaction, the insider now owns 83,172 shares in the company, valued at $389,244.96. The transaction was disclosed in a document filed with the SEC, which is available at this link. Insiders own 11.30% of the company’s stock.
A number of institutional investors have recently bought and sold shares of the business. Bank of New York Mellon Corp grew its position in Amyris by 16.3% in the second quarter. Bank of New York Mellon Corp now owns 32,768 shares of the biotechnology company’s stock worth $104,000 after buying an additional 4,603 shares during the last quarter. KBC Group NV boosted its stake in Amyris by 228.4% in the 3rd quarter. KBC Group NV now owns 60,154 shares of the biotechnology company’s stock worth $192,000 after purchasing an additional 41,834 shares during the period. Creative Planning acquired a new position in Amyris in the 4th quarter worth approximately $188,000. Carl Domino Inc acquired a new position in Amyris in the 3rd quarter worth approximately $182,000. Finally, Hudson Bay Capital Management LP acquired a new position in Amyris in the 4th quarter worth approximately $451,000. Hedge funds and other institutional investors own 22.93% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Amyris’ (NASDAQ:AMRS) “Buy” Rating Reiterated at HC Wainwright” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/02/13/amyris-amrs-earns-buy-rating-from-hc-wainwright.html.
Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.
Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.